0.31 USD
+0 (+0.98%)
Last: Feb 2, 2026, 10:03 AM
Taking everything into account, ITRM scores 1 out of 10 in our fundamental rating. ITRM was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ITRM have multiple concerns. ITRM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- In the past year ITRM has reported negative net income.
- In the past year ITRM has reported a negative cash flow from operations.
- ITRM had negative earnings in each of the past 5 years.
- In the past 5 years ITRM always reported negative operating cash flow.
1.2 Ratios
- ITRM's Return On Assets of -82.95% is on the low side compared to the rest of the industry. ITRM is outperformed by 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.95% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-89.08%
ROA(5y)-105.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ITRM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for ITRM has been increased compared to 1 year ago.
- Compared to 5 years ago, ITRM has more shares outstanding
- The debt/assets ratio for ITRM is higher compared to a year ago.
2.2 Solvency
- ITRM has an Altman-Z score of -23.38. This is a bad value and indicates that ITRM is not financially healthy and even has some risk of bankruptcy.
- ITRM has a Altman-Z score of -23.38. This is amonst the worse of the industry: ITRM underperforms 85.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -23.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 2.13 indicates that ITRM has no problem at all paying its short term obligations.
- ITRM's Current ratio of 2.13 is in line compared to the rest of the industry. ITRM outperforms 40.31% of its industry peers.
- ITRM has a Quick Ratio of 1.96. This is a normal value and indicates that ITRM is financially healthy and should not expect problems in meeting its short term obligations.
- ITRM has a Quick ratio (1.96) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.13 | ||
| Quick Ratio | 1.96 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 63.50% over the past year.
EPS 1Y (TTM)63.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- ITRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.81% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.09%
EPS Next 2Y34.1%
EPS Next 3Y27.71%
EPS Next 5Y23.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ITRM. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITRM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ITRM's earnings are expected to grow with 27.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.1%
EPS Next 3Y27.71%
5. Dividend
5.1 Amount
- ITRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ITERUM THERAPEUTICS PLC / ITRM FAQ
What is the ChartMill fundamental rating of ITERUM THERAPEUTICS PLC (ITRM) stock?
ChartMill assigns a fundamental rating of 1 / 10 to ITRM.
What is the valuation status for ITRM stock?
ChartMill assigns a valuation rating of 1 / 10 to ITERUM THERAPEUTICS PLC (ITRM). This can be considered as Overvalued.
What is the profitability of ITRM stock?
ITERUM THERAPEUTICS PLC (ITRM) has a profitability rating of 0 / 10.